Minjuvi® Approved in Australia for Relapsed Follicular Lymphoma Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy INCY?
Source: Newsfilter
- First Chemotherapy-Free Option: Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy regimen approved in Australia, addressing a critical gap in treatment for patients with relapsed follicular lymphoma and expected to significantly enhance patient quality of life.
- Clinical Trial Results: In the global Phase 3 inMIND clinical study involving 652 patients, the Minjuvi combination regimen achieved a median progression-free survival (PFS) of 22.4 months compared to 13.9 months in the control group, representing a 57% reduction in the risk of disease progression, relapse, or death, demonstrating significant efficacy.
- Meeting Patient Needs: Approximately 1,500 Australians are diagnosed with follicular lymphoma each year, and despite existing treatments, relapsed follicular lymphoma remains incurable; the approval of Minjuvi provides new hope for these patients, fulfilling the urgent need for effective therapies.
- Strategic Partnership Advancement: Specialised Therapeutics has entered into an exclusive distribution agreement with Incyte to commercialize Minjuvi in Australia, New Zealand, and Singapore, marking the company's ongoing commitment to meet patient needs in the Asia-Pacific region.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INCY
Wall Street analysts forecast INCY stock price to rise
19 Analyst Rating
9 Buy
9 Hold
1 Sell
Moderate Buy
Current: 96.220
Low
73.00
Averages
100.31
High
125.00
Current: 96.220
Low
73.00
Averages
100.31
High
125.00
About INCY
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Minjuvi® Approved in Australia for Relapsed Follicular Lymphoma Treatment
- First Chemotherapy-Free Option: Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy regimen approved in Australia, addressing a critical gap in treatment for patients with relapsed follicular lymphoma and expected to significantly enhance patient quality of life.
- Clinical Trial Results: In the global Phase 3 inMIND clinical study involving 652 patients, the Minjuvi combination regimen achieved a median progression-free survival (PFS) of 22.4 months compared to 13.9 months in the control group, representing a 57% reduction in the risk of disease progression, relapse, or death, demonstrating significant efficacy.
- Meeting Patient Needs: Approximately 1,500 Australians are diagnosed with follicular lymphoma each year, and despite existing treatments, relapsed follicular lymphoma remains incurable; the approval of Minjuvi provides new hope for these patients, fulfilling the urgent need for effective therapies.
- Strategic Partnership Advancement: Specialised Therapeutics has entered into an exclusive distribution agreement with Incyte to commercialize Minjuvi in Australia, New Zealand, and Singapore, marking the company's ongoing commitment to meet patient needs in the Asia-Pacific region.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, including successful launches of innovative therapies at Arcutis Biotherapeutics and Incyte, which is expected to significantly enhance Palvella's sales leadership and market insights.
- Market Potential: Taylor will lead the U.S. sales efforts for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is projected to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a critical market gap.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent to drive business growth in high unmet need areas of dermatology.
- Product Pipeline: Palvella is developing multiple product candidates based on its QTORIN™ platform, and Taylor's extensive experience will help accelerate the market introduction of these products, particularly in areas lacking FDA-approved therapies, further enhancing the company's competitive edge.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, having previously held executive roles at Arcutis Biotherapeutics and Incyte, where he successfully led the launches of ZORYVE® and OPZELURA®, which is expected to significantly enhance Palvella's sales leadership and market insight.
- Market Potential: Taylor will oversee the U.S. sales for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is anticipated to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a significant unmet need in the market.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent, aiming to build a robust sales organization to support future product launches and market expansion.
- Industry Experience: Taylor's extensive experience in dermatology will facilitate closer collaborations with dermatologists, particularly pediatric dermatologists, further driving market acceptance and sales growth for the QTORIN™ platform.
See More
Trump May Announce New Drug Tariffs Soon
- New Tariff Policy: President Trump may announce a 100% tariff on pharmaceutical and biotech companies that have not signed 'most favored nation' agreements, aimed at reducing drug prices for Americans and impacting companies that have not reached agreements.
- Tariff Details: According to a Commerce Department investigation, companies that onshore manufacturing to the U.S. will face a 20% tariff lasting four years, while products from certain countries will incur only a 15% tariff, indicating preferential treatment for specific nations.
- Scope of Impact: Most major pharmaceutical companies have signed MFN agreements with the Trump administration; however, Regeneron Pharmaceuticals has yet to do so, potentially facing direct impacts from the new tariffs that could increase operational costs.
- Industry Opposition: The Midsized Biotech Alliance of America has opposed the 'most favored nation' policy, labeling it as 'importing foreign price controls,' reflecting concerns within the industry about the new policy and its potential negative implications.
See More
Adagene and Incyte Collaborate on Clinical Study for MSS CRC
- Clinical Collaboration Initiated: Adagene and Incyte are collaborating on a study evaluating the combination of INCA33890 and muzastotug in 3L MSS CRC patients, expected to begin in 2026, aiming to explore the potential of novel immunotherapies to improve patient outcomes.
- Drug Combination Validation: The combination of muzastotug with Merck's KEYTRUDA has shown promising overall response rates in previous trials, indicating its potential as a backbone therapy for next-generation immuno-oncology combinations.
- Study Design Details: The study will first assess safety and tolerability, followed by an efficacy expansion cohort focusing on chemotherapy-refractory MSS CRC patients, aiming to provide new treatment options for this challenging disease.
- Technological Advantage Showcase: Adagene's SAFEbody technology is once again leveraged in this collaboration, highlighting its potential to enhance the safety and tolerability of immunotherapies, which may offer broader applications in future cancer treatments.
See More
Povorcitinib Shows Significant Efficacy in Hidradenitis Suppurativa Treatment
- Significant Clinical Efficacy: The 54-week data from the STOP-HS program demonstrated that 71.4% of patients achieved HiSCR50 with povorcitinib, indicating substantial long-term efficacy in moderate to severe hidradenitis suppurativa (HS) patients, potentially transforming treatment paradigms.
- Good Safety Profile: The safety data over 54 weeks showed that treatment-emergent adverse events (TEAEs) occurred in 76.2% to 83.4% of patients, mostly mild to moderate, indicating a favorable tolerance for povorcitinib.
- Quality of Life Improvements: At Week 54, 40.5% to 46.8% of patients reported significant improvements in skin pain, and 49.0% to 58.0% experienced reductions in fatigue, suggesting that povorcitinib not only alleviates pathological symptoms but also enhances overall quality of life.
- Regulatory Application Progress: The STOP-HS data support the New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib, which are currently under review by the U.S. FDA and European Medicines Agency, indicating its potential as the first oral treatment option for HS patients.
See More
Minjuvi® Approved in Australia for Relapsed Follicular Lymphoma Treatment
- First Chemotherapy-Free Option: Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy regimen approved in Australia, addressing a critical gap in treatment for patients with relapsed follicular lymphoma and expected to significantly enhance patient quality of life.
- Clinical Trial Results: In the global Phase 3 inMIND clinical study involving 652 patients, the Minjuvi combination regimen achieved a median progression-free survival (PFS) of 22.4 months compared to 13.9 months in the control group, representing a 57% reduction in the risk of disease progression, relapse, or death, demonstrating significant efficacy.
- Meeting Patient Needs: Approximately 1,500 Australians are diagnosed with follicular lymphoma each year, and despite existing treatments, relapsed follicular lymphoma remains incurable; the approval of Minjuvi provides new hope for these patients, fulfilling the urgent need for effective therapies.
- Strategic Partnership Advancement: Specialised Therapeutics has entered into an exclusive distribution agreement with Incyte to commercialize Minjuvi in Australia, New Zealand, and Singapore, marking the company's ongoing commitment to meet patient needs in the Asia-Pacific region.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, including successful launches of innovative therapies at Arcutis Biotherapeutics and Incyte, which is expected to significantly enhance Palvella's sales leadership and market insights.
- Market Potential: Taylor will lead the U.S. sales efforts for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is projected to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a critical market gap.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent to drive business growth in high unmet need areas of dermatology.
- Product Pipeline: Palvella is developing multiple product candidates based on its QTORIN™ platform, and Taylor's extensive experience will help accelerate the market introduction of these products, particularly in areas lacking FDA-approved therapies, further enhancing the company's competitive edge.
See More
Palvella Appoints New Senior Vice President of Sales
- Executive Appointment: Palvella Therapeutics has appointed Kent Taylor as Senior Vice President of Sales, bringing over 25 years of pharmaceutical experience, having previously held executive roles at Arcutis Biotherapeutics and Incyte, where he successfully led the launches of ZORYVE® and OPZELURA®, which is expected to significantly enhance Palvella's sales leadership and market insight.
- Market Potential: Taylor will oversee the U.S. sales for Palvella's upcoming QTORIN™ rapamycin, targeting microcystic lymphatic malformations, which is anticipated to provide the first FDA-approved treatment for over 30,000 diagnosed patients in the U.S., addressing a significant unmet need in the market.
- Strategic Development: Taylor's addition not only strengthens Palvella's market position in rare skin diseases and vascular malformations but also reflects the company's commitment to attracting top talent, aiming to build a robust sales organization to support future product launches and market expansion.
- Industry Experience: Taylor's extensive experience in dermatology will facilitate closer collaborations with dermatologists, particularly pediatric dermatologists, further driving market acceptance and sales growth for the QTORIN™ platform.
See More
Trump May Announce New Drug Tariffs Soon
- New Tariff Policy: President Trump may announce a 100% tariff on pharmaceutical and biotech companies that have not signed 'most favored nation' agreements, aimed at reducing drug prices for Americans and impacting companies that have not reached agreements.
- Tariff Details: According to a Commerce Department investigation, companies that onshore manufacturing to the U.S. will face a 20% tariff lasting four years, while products from certain countries will incur only a 15% tariff, indicating preferential treatment for specific nations.
- Scope of Impact: Most major pharmaceutical companies have signed MFN agreements with the Trump administration; however, Regeneron Pharmaceuticals has yet to do so, potentially facing direct impacts from the new tariffs that could increase operational costs.
- Industry Opposition: The Midsized Biotech Alliance of America has opposed the 'most favored nation' policy, labeling it as 'importing foreign price controls,' reflecting concerns within the industry about the new policy and its potential negative implications.
See More
Adagene and Incyte Collaborate on Clinical Study for MSS CRC
- Clinical Collaboration Initiated: Adagene and Incyte are collaborating on a study evaluating the combination of INCA33890 and muzastotug in 3L MSS CRC patients, expected to begin in 2026, aiming to explore the potential of novel immunotherapies to improve patient outcomes.
- Drug Combination Validation: The combination of muzastotug with Merck's KEYTRUDA has shown promising overall response rates in previous trials, indicating its potential as a backbone therapy for next-generation immuno-oncology combinations.
- Study Design Details: The study will first assess safety and tolerability, followed by an efficacy expansion cohort focusing on chemotherapy-refractory MSS CRC patients, aiming to provide new treatment options for this challenging disease.
- Technological Advantage Showcase: Adagene's SAFEbody technology is once again leveraged in this collaboration, highlighting its potential to enhance the safety and tolerability of immunotherapies, which may offer broader applications in future cancer treatments.
See More
Povorcitinib Shows Significant Efficacy in Hidradenitis Suppurativa Treatment
- Significant Clinical Efficacy: The 54-week data from the STOP-HS program demonstrated that 71.4% of patients achieved HiSCR50 with povorcitinib, indicating substantial long-term efficacy in moderate to severe hidradenitis suppurativa (HS) patients, potentially transforming treatment paradigms.
- Good Safety Profile: The safety data over 54 weeks showed that treatment-emergent adverse events (TEAEs) occurred in 76.2% to 83.4% of patients, mostly mild to moderate, indicating a favorable tolerance for povorcitinib.
- Quality of Life Improvements: At Week 54, 40.5% to 46.8% of patients reported significant improvements in skin pain, and 49.0% to 58.0% experienced reductions in fatigue, suggesting that povorcitinib not only alleviates pathological symptoms but also enhances overall quality of life.
- Regulatory Application Progress: The STOP-HS data support the New Drug Application (NDA) and Marketing Authorization Application (MAA) for povorcitinib, which are currently under review by the U.S. FDA and European Medicines Agency, indicating its potential as the first oral treatment option for HS patients.
See More
